Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1357-1361

  Price, Elizabeth A ^a   Hayward, Catherine P M ^b   Moffat, Karen A ^b,c   Moore, Jane C ^b   Warkentin, Theodore E ^b   Zehnder, James L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

Heparin induced thrombocytopenia; Laboratory diagnosis; Platelet factor 4; Thrombocytopenia

Indexed keywords

HEPARIN; IMMUNOGLOBULIN; SEROTONIN;

ANTIBODY DETECTION; ARTICLE; BLOOD CLOTTING; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; INFORMATION PROCESSING; LABORATORY TEST; MATERIALS HANDLING; METHODOLOGY; NORTH AMERICA; ONLINE SYSTEM; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SEROTONIN RELEASE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ANTICOAGULANTS; COHORT STUDIES; DIAGNOSTIC SERVICES; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEMATOLOGY; HEPARIN; HUMANS; IMMUNOASSAY; INTERNET; LABORATORIES; NORTH AMERICA; PLATELET FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; QUALITY CONTROL; QUALITY OF HEALTH CARE; QUESTIONNAIRES; REAGENT KITS, DIAGNOSTIC; THROMBOCYTOPENIA;

EID: 36949007618     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0401     Document Type: Article

References (34)

1. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
2. Greinacher A, Eichler P, Lietz T, et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 2005; 106: 2921-2922.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
4. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-2524.
5. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
6. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb ffaemost 2005; 94: 132-135.
7. Fontana P, Bodmer A, Gruel Y, et al. Skin necrosis is a clinical manifestation of low-molecular weight heparin-induced thrombocytopenia. Thromb Haemost 2004; 91: 196-197.
8. Lubenow N, Kempf R, Eichner A, et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122; 37-42.
9. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136: 210-215.
10. Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 2005; 45: 417-419.
11. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
12. Visentin GP Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
13. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
14. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 2346-2353.
15. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127 (2 Suppl): 35S-45S.
16. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 311S-37S.
17. Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-706.
18. Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23: 745-753.
19. Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006; 20: 259-272.
20. Institute GT. PF4 Enhanced. 2005. Available from: http://www.gfidiagnostics.com/documentation/coag/ xhat13&45_di_eng_011305.pdf.
21. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti- PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006; 4: 281-282.
22. Refaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin-induced thrombocytopenia. relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 2003; 119: 497-504.
23. Amiral J, Wolf M, Fischer A, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954-959.
24. Amiral J, Bridey E. Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73: 21-28.
25. Lindhoff-Last E, Eichler P, Stein M, et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery Thromb Res 2000; 97: 387-393.
26. Suh JS, Malik MI, AsterRH, et al. Characterization of the Immoral immune response in heparin-induced thrombocytopenia. Am J Hematol 1997; 54: 196-201.
27. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146: 341-346.
28. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
29. Davoren A, Aster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hernatol 2006; 81: 36-44.
30. Zwicker JI, Uhl L, Huang WY, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2: 2133-2137.
31. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 2002; 252: 149-154.
32. Warkentin TE, Hayward CP, Smith CA, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371-379.
33. Francis JL. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex. Semin Thromb Hemost 2004; 30: 359-368.
34. Francis JL. Detection and significance of heparin-platelet factor 4 antibodies, Semin Hematol 2005; 42 (3 Suppl 3): S9-14.